These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9735408)

  • 21. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of p53 mutation in pancreatic acinar cell carcinomas of humans and transgenic mice.
    Terhune PG; Memoli VA; Longnecker DS
    Pancreas; 1998 Jan; 16(1):6-12. PubMed ID: 9436856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
    Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
    Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance of p53 mutations of synchronous colorectal carcinomas.
    Eguchi K; Yao T; Konomoto T; Hayashi K; Fujishima M; Tsuneyoshi M
    Mod Pathol; 2000 Feb; 13(2):131-9. PubMed ID: 10697269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer.
    Banelli B; Casciano I; Di Vinci A; Gatteschi B; Levaggi A; Carli F; Bighin C; Salvi S; Allemanni G; Ghiorzo P; Pronzato P; Venturini M; Romani M; Del Mastro L
    Ann Oncol; 2010 Jun; 21(6):1237-1242. PubMed ID: 19875753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
    Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
    Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma.
    van Rens MT; Eijken EJ; Elbers JR; Lammers JW; Tilanus MG; Slootweg PJ
    Cancer; 2002 Jan; 94(1):188-96. PubMed ID: 11815976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
    Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
    Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
    J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
    Phillips KA; Nichol K; Ozcelik H; Knight J; Done SJ; Goodwin PJ; Andrulis IL
    J Natl Cancer Inst; 1999 Mar; 91(5):469-73. PubMed ID: 10070948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
    Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
    Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
    J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis.
    Uzawa K; Ono K; Suzuki H; Tanaka C; Yakushiji T; Yamamoto N; Yokoe H; Tanzawa H
    Clin Cancer Res; 2002 Mar; 8(3):828-35. PubMed ID: 11895916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonality analysis of multifocal ipsilateral breast carcinomas using X-chromosome inactivation patterns.
    Kim H; Kim CY; Park KH; Kim A
    Hum Pathol; 2018 Aug; 78():106-114. PubMed ID: 29727695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue.
    Kopp P; Jaggi R; Tobler A; Borisch B; Oestreicher M; Sabacan L; Jameson JL; Fey MF
    Mol Cell Probes; 1997 Jun; 11(3):217-28. PubMed ID: 9232621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
    Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
    Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of mutant-type p53 expression in squamous cell carcinoma of the head and neck during radiation therapy and its clinical significance: comparison of an immunohistochemical method and PCR-SSCP assay.
    Ogawa Y; Nishioka A; Hamada N; Terashima M; Inomata T; Yoshida S; Seguchi H; Kishimoto S
    Oncol Rep; 1998; 5(5):1053-9. PubMed ID: 9683807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
    Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
    Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.